Skip to main content
Preliminary data show gene therapy beneficial to hemophilia A patients

Updated preliminary follow-up data from the Phase I/II trial assessing the gene therapy candidate SB-525, being jointly developed by Pfizer and Sangamo Therapeutics, shows clinically relevant and stable improvements in eight patients with hemophilia A, who subsequently experienced a notably reduced need for replacement therapy. A presentation of the new data will be made during the 2019 Congress of the International Society on Thrombosis and Haemostasis.

Full Story: